Array Biopharma
FDA Approves Braftovi, Erbitux Combination for BRAF V600E-Mutated Colorectal Cancer Patients
Encorafenib (Pfizer/Array BioPharma's Braftovi) is approved in combination with cetuximab (Eli Lilly's Erbitux) for previously treated patients.
BEACON Trial Reports Survival Benefit for Triple Targeted Treatment in BRAF-Mutated Metastatic CRC
An international team saw an overall survival benefit when using BRAF, MEK, and EGFR inhibitors together in previously treated, BRAF-mutated metastatic colorectal cancer patients.